Clinical psychologist and psychotherapist, part-time researcher with a focus on suicide prevention and psychopharmacology.
https://ploederlm.github.io/publications/
https://scholar.google.at/citations?user=76cO6AEAAAAJ&hl=de
Nature, espresso, cycling.
Martin Plöderl
Loading...
Dylan, on life in your 80’s, is incredible.
@nytimes.com
www.nytimes.com/2026/06/14/o...
Carl Quintanilla
Beautiful Salzburg
Current issues with biological psychiatry in one sentence 😅
Martin Plöderl
Martin Plöderl
This reflection from David Jobes on his career and working with suicidal individuals is beautiful. Thanks Dave ☺️
link.springer.com/article/10.1...
#suicideprevention
This article describes a professional journey in the field of clinical suicidology that led to the creation and the development of an evidence-based, suicide-focused, clinical treatment called the “Co...
5. For antidepressants, it is often said that they don't work well for depression but effects are larger for anxiety and OCD. True, according to the RCTs. However, we simply lack newer, less biased trials, so this statement is problematic. Good discussion by Cohen et al. on this issue.
1. Antidepressants for OCD - sponsorship bias?
Only few RCTs compared the new drug to an older drug (and placebo). Look what happens to clomipramine in the single RCT where it was the comparator drug (to paroxetine).
It melts down from SMD > 1 to SMD 0.4.
3. IMO and also according to Cohen et al. from which I used the data and which is a great analysis, these trials should be treated with scepticism: they are all older, rarely pre-registered, with associated risk of biases.
2. However, this was not so for paroxetine which served as comparison drug to escitalopram
6. See the sponsorship bias in pediatric fluoxetine trials. Effects as mean diffs in the CDRS-R. Effects reduce from MD = 6 in RCTs sponsored by Eli Lilly (producer of fluoxetine) to MD = 2.5 when fluoxetine was used in an additional arm in RCTs from competing companies. See our 2026 (ref above).
4. As we have shown for fluoxetine, once it was used as comparator drug, efficacy diminished. This confirms research among adults. Moreover, efficacy generally declined for investigated antidepressants.
www.jclinepi.com/article/S089...
